The P2X3 receptor is a ligand-gated ion channel belonging to the P2X family of purinergic receptors, which respond to extracellular adenosine triphosphate (ATP). Encoded by the P2RX3 gene located on chromosome 11q33, P2X3 forms homotrimeric channels that are predominantly expressed in sensory neurons of the dorsal root ganglia (DRG), trigeminal ganglia, and nodose ganglia. This receptor is particularly enriched in small-diameter nociceptive and chemosensitive neurons, where it plays a critical role in acute pain signaling and other sensory functions. The P2X3 receptor exists as both functional homotrimers and can also form heterotrimeric channels with the closely related P2X2 subunit, creating P2X2/3 receptors with distinct pharmacological and biophysical properties.
Function/Biology
As an ionotropic receptor, P2X3 mediates rapid ATP-evoked cation influx (primarily calcium and sodium) when activated by extracellular ATP or ATP analogs such as α,β-methylene ATP (α,β-MeATP). Upon ATP binding to its ligand-binding domain, the receptor undergoes conformational changes that open a central pore, allowing ion permeation within milliseconds. This rapid response makes P2X3 an effective signal transducer for acute sensory stimuli. The receptor exhibits calcium permeability (PCa/PNa ratio approximately 5), enabling robust calcium signaling that triggers intracellular cascades through calcium-dependent enzymes including kinases and phosphatases.
...
P2X3 Receptor Protein
Overview
The P2X3 receptor is a ligand-gated ion channel belonging to the P2X family of purinergic receptors, which respond to extracellular adenosine triphosphate (ATP). Encoded by the P2RX3 gene located on chromosome 11q33, P2X3 forms homotrimeric channels that are predominantly expressed in sensory neurons of the dorsal root ganglia (DRG), trigeminal ganglia, and nodose ganglia. This receptor is particularly enriched in small-diameter nociceptive and chemosensitive neurons, where it plays a critical role in acute pain signaling and other sensory functions. The P2X3 receptor exists as both functional homotrimers and can also form heterotrimeric channels with the closely related P2X2 subunit, creating P2X2/3 receptors with distinct pharmacological and biophysical properties.
Function/Biology
As an ionotropic receptor, P2X3 mediates rapid ATP-evoked cation influx (primarily calcium and sodium) when activated by extracellular ATP or ATP analogs such as α,β-methylene ATP (α,β-MeATP). Upon ATP binding to its ligand-binding domain, the receptor undergoes conformational changes that open a central pore, allowing ion permeation within milliseconds. This rapid response makes P2X3 an effective signal transducer for acute sensory stimuli. The receptor exhibits calcium permeability (PCa/PNa ratio approximately 5), enabling robust calcium signaling that triggers intracellular cascades through calcium-dependent enzymes including kinases and phosphatases.
P2X3 receptors are subject to rapid desensitization—a hallmark feature of P2X channels—wherein continued ATP exposure leads to channel closure despite sustained agonist presence. This desensitization occurs through conformational trapping and contributes to the phasic nature of P2X3-mediated signaling. Additionally, P2X3 undergoes dynamic trafficking, phosphorylation by protein kinase C and other kinases, and regulation through interactions with scaffold proteins that modulate its surface expression and channel properties.
Role in Neurodegeneration
Emerging evidence implicates P2X3 dysregulation in various neurodegenerative conditions affecting sensory and autonomic systems. Aberrant P2X3 signaling contributes to neuroinflammation through excessive calcium influx and subsequent mitochondrial dysfunction, triggering neurotoxic cascades including oxidative stress generation and apoptosis. In dorsal root ganglia affected by diabetic neuropathy, upregulated P2X3 expression correlates with enhanced nociceptive sensitization and neuronal dysfunction. Similarly, in small fiber neuropathies—conditions characterized by selective degeneration of small-diameter sensory neurons—P2X3 overactivation precipitates calcium overload and energy depletion in these metabolically vulnerable neurons.
P2X3 also participates in autonomic neuron degeneration relevant to conditions like Parkinson's disease and multiple system atrophy, where sensory and autonomic ganglia are affected. Chronic ATP elevation in neurodegenerative microenvironments promotes sustained P2X3 activation, exhausting cellular protective mechanisms and accelerating neuron death through excitotoxicity.
Molecular Mechanisms
P2X3 activation initiates multiple intracellular pathways: calcium influx activates calmodulin-dependent protein kinase II (CaMKII), triggering phosphorylation cascades that amplify inflammatory signals through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Persistent calcium elevation impairs mitochondrial function, reducing ATP production and promoting reactive oxygen species (ROS) generation. Additionally, P2X3-mediated signaling intersects with inflammatory cytokine pathways, particularly through tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which upregulate P2X3 expression in a positive feedback loop.
Clinical/Research Significance
P2X3 antagonists represent a therapeutic avenue for sensory neuropathies and chronic pain. Gefapixant, a selective P2X3 antagonist, demonstrates efficacy in reducing refractory chronic cough and shows promise in clinical trials for neuropathic pain. A-317491, another P2X3-selective antagonist, exhibits analgesic properties in preclinical models. These compounds, by blocking excessive P2X3 signaling, may protect sensory neurons from excitotoxic degeneration while alleviating pain symptoms. Research exploring P2X3 modulation in neurodegenerative contexts may yield neuroprotective strategies targeting ATP-driven neuroinflammation and excitotoxicity.
Related Entities
P2X2 receptor (forms heteromeric channels with P2X3)
P2X7 receptor (alternative purinergic pathway in neuroinflammation)
ATP metabolism and extracellular adenosine metabolism